| Name | Title | Contact Details |
|---|
Ascend Health Services is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
United! International Laboratories is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT™ Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.
Impact Cryotherapy is the national leader in designing and manufacturing whole body cryotherapy systems. The company`s state-of-the-art cryosaunas are sleek, attractive single-person chambers that are engineered and manufactured in the United States in an ISO 9001 certified facility. Impact Cryotherapy is redefining the age-old technique of cryotherapy with advanced technology and aesthetics to deliver unmatched efficiency, comfort and reliability.
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.